logo
Tim Spector: The five health tips I'd give my 20-year-old self

Tim Spector: The five health tips I'd give my 20-year-old self

Yahoo01-07-2025
I spent my 20s studying as a medical student and then working as a junior doctor. My life was what I could fit in around incredibly tough hours, often barely sleeping or having any time to think about food or exercise at all.
It was the 1980s and I was hopping around hospitals in London. I would have loved for someone to tell me about the importance of diet and lifestyle, how to develop healthy habits and how much they're needed later in life. That would have been really helpful.
Most people are certainly not leading balanced lives in their 20s, and yet recover because they're young and resilient. Nonetheless, it's important to start being healthy as early as you can.
Around a decade ago, my son, Tom, did an experiment I was going to do myself as part of his genetics degree dissertation. The experiment involved eating McDonald's twice a day for 10 days to see how it would affect his gut health. He lost 30 per cent of his gut microbes and it took him years to recover them.
So, if you abuse your health and gut microbes, even in your youth, it can take a long time for them to recover. I wish I'd known this.
No one ever talked about the importance of sleep back when I was in my 20s.
For those intensive years as a junior doctor, I was sleep-deprived most of the time. I was regularly working 72-hour shifts on just a few hours of sleep and then binge sleeping on the days I wasn't on the ward. I knew how to crash out at 6pm after a long shift and wake at 8am the next morning.
We didn't really question it, as you knew your bosses had done the same, and you got more experience much faster by working long shifts – it was just the sacrifice you made as a doctor. But I couldn't do it again, that's for sure.
Researchers recently worked out that functioning on such little sleep is equivalent to going around having drunk half a bottle of wine when you're seeing patients. So we really weren't at our best and shouldn't have been allowed near a car, but, after a few years, if you didn't make too many blunders, you had seen everything, so it did prepare us for the future.
If you could do without sleep, you were seen as cool and the toughest of the junior doctors. It was a badge of honour if you could make do on only four hours a night.
If you could cope well on little sleep and, importantly, fall back to sleep easily, you would often do acute or emergency work. I didn't cope with it well, so I went for a specialty where I didn't have to get up routinely at night, which was rheumatology. However, it took a long time, a lot of work, and a few sleepless nights to get there.
I do try to sleep much more evenly now that I realise how important it is for our health. Our research at ZOE has found that people who don't sleep for long enough or have poor sleep quality have much larger spikes in their blood sugar levels the next day, leaving them hungry and seeking carbs. Regularly changing your sleep schedule also has an impact.
As a result, I now aim to be in bed before 11pm every night, to try and keep my sleep timings as consistent as possible. I also wear earplugs and an eye mask, and I've changed my curtains to blackout. I also stop using my phone after 10 pm to get rid of anything that could disrupt my sleep and reduce its quality. This has really helped.
Most of the stuff I was eating in my 20s was fairly revolting, apart from days when I'd dine out at an Italian or Indian restaurant, which was a rare treat and meant I'd have some decent food.
My breakfast was cereal or toast and marmalade – croissants and pastries weren't a big thing in the 80s.
Lots of my other meals were hospital food, which was absolutely appalling and probably hasn't improved much. I would often get an English breakfast or a plate of chips from the canteen, and there wasn't a vegetable in sight. Or I would pick up a tuna sandwich from the hospital cafe – I wasn't strong enough to resist the lure of the meal deal.
For snacks, I had too much low-quality toast, as you could get it at any time of the day or night on the wards. It was always a nice comfort treat, but I would have been much better off munching on a large handful of nuts, or even dark chocolate, rather than bread, which spiked my blood sugar.
I might have had a yogurt once a week, but it was a flavoured one and probably low-fat, which is much less healthy. Only women and kids had yogurt in those days; it wasn't a macho thing to have. I also used to love orange juice. I wish someone had told me that it was not a 'health food' and was actually bad for me.
The occasional banana was about the only fruit I remember eating. I was probably fairly constipated and would have definitely benefited from more fibre.
It's pretty grim when I think about what I was eating – it's amazing I'm still alive. But when you're young, you're pretty resilient.
I don't really blame my old self because it was really tough. Faced with long working hours, survival was really all I was interested in. And we didn't question things back then. We had no real concept of health. I thought rice was healthy, and fat of any kind might be bad for you – so not cooking with too much olive oil, butter or lard – but that was about it.
In retrospect, getting more variety would have been good. Now, I always aim for 30 plants a week, carry around some mixed nuts and seeds, and include fermented food at most meals.
I also had no concept of giving my gut a rest, so I was basically eating all the time, as 'little and often' was the current dogma. Eating better would have stopped my weight from creeping up. I was pretty skinny when I started medicine, around 11st (70kg), and when I was really busy, it stayed at that level until I was 30, but then it started to increase by about a kilogram per year.
Obviously, like nearly everyone, I drank too much in my 20s but that was the culture then. When we weren't working really hard, we'd be out partying.
When I was based at St Bart's Hospital in central London, it was opposite Smithfield meat market, where you could always find somewhere for a drink at any hour of the day or night. There was also our own cheap student bar that was open until 3am.
I drank anything I could get hold of – I wasn't very fussy. I'd have beers, wine, gin or vodka, though I didn't smoke or take drugs. My mum had put me off smoking as she was a chain smoker.
These days, I aim for a maximum of 14 units a week (equivalent to seven 175ml glasses of wine or seven pints of low-strength beer). I've talked about the modest cardiac benefits of red wine, but that's not all I drink – I enjoy beer, and I'll have the occasional gin and tonic.
I aim to have a couple of alcohol-free days a week, but that goes to pot on holidays. But I'm now a big fan of alcohol free beers and kombucha, which are tasty non-alcoholic options.
I played cricket and rugby at school and university, but I didn't do much exercise in my 20s. I probably should have, but I wasn't aware of any of my colleagues having the time to do any either.
Saying that, I'm sure we were hitting around 20,000 steps a day on the days we were working, because we were just used as slaves to do everything all over the hospital. I was running up and down really long corridors for days on end.
I also would pick up running each time I had an exam, which there are lots of in medicine, even after you qualify. I didn't particularly enjoy it as exercise, but it was effective at reducing stress and clearing my mind. I remember thinking: 'Oh my god, I can't study anymore, I've got to go for a run'.
It would have been great to have been introduced to yoga or pilates, as that would have helped me later in life with being more flexible because, like most people, I ended up having back pain in my early 30s. This was because my toes seemed a long way from my fingers, and I'd never stretched in my life.
I got better at exercising in my 30s; I'd go to the gym once a week. They didn't really exist before that unless you were a bodybuilder, which I was not – I was quite puny. Dance classes and aerobics also took off, so I did that for a while, but never very seriously.
These days, I mix it up. I do some yoga classes, I'll do some weights, and cycle for real or on my Peloton bike. In the summer, I swim most days and do mountain biking. Just as with food, a variety of exercise is good as it uses different muscles and different parts of the brain.
I was dreadful at staying in touch with my family in my 20s. I left home at 17 and rarely saw my parents – maybe two or three times a year, which is completely different to how often I see my own kids now.
But that was cultural – I don't think I was very different from my friends and colleagues. We all rebelled against our parents, and it was a very different scene.
What's important is that you have a support group to link up with. It doesn't have to be your parents, it could be close friends or another form of community, so you don't get isolated. I wish someone had told me that when you're young, you make a lot of your best friends, who you keep with you all your life. I still see many of my school friends regularly and realise how supportive it is to have regular contact and a good dose of sarcastic teasing.
Make time to catch up with old friends and your parents. It's the friends that drift off; your parents will usually be there – though they're not always, if they die early like my father did when I was 21. I regret not spending more time with him.
Meeting socially is important for longevity. With my family, we do Christmas together, have an annual skiing holiday together, and, when we're in London, we have a Sunday lunch or meal out every other week. We see quite a lot of each other, but not so much that we're sick of each other and start fighting.
All in all, I feel immensely grateful to be fit and well, given the way I mistreated my body in my youth. It's a testament to the resilience of life and our bodies. We can't turn back the clock, but we can start afresh today. Eating a diverse range of plants, limiting alcohol, keeping active and maintaining close relationships are all evidence-based ways to stay healthy as we age.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca CFO talks tariffs & shifting focus to US market
AstraZeneca CFO talks tariffs & shifting focus to US market

Yahoo

time7 hours ago

  • Yahoo

AstraZeneca CFO talks tariffs & shifting focus to US market

AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market. AstraZeneca CFO Aradhana Sarin sits down with Market Catalysts host Julie Hyman and Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani to discuss the company's strategy to focus on the US and the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. I wonder on the Obviously, the company is celebrating the fact that you hit the largest revenues reported for the quarter. That's really good news, especially as the stated goal is to grow by 2030, and half of that to be part of the US. Talk to me about that and the shift to being a quote-unquote American company now, rather than a sort of UK-based one that we've thought of all these years. Uh, so we, you know, last May, we set this ambition of achieving 80 billion in revenues by 2030, which was almost, you know, doubling our revenues from a 2023 base. Um, and, uh, the US is our our fastest growing market. Uh, when we stack, we don't stack very highly right now, uh, in the US when when you compare pharma revenues because a lot of the pharma companies in the US have much bigger sort of revenue base, but we're growing very fast and our hope is that we'll come, you know, in in in the top five and have half of our revenue. We also set an ambition to have 20 new medicines by 2030. And, um, we already have nine of them and, uh, we announced results for another five of them. So hopefully, uh, that shows that we're on track to to achieve that goal. Well, talk to me about why the US is growing that much far faster. Is it because the dynamics of the healthcare system help boost revenues with more prescribing the the way the PBM system is set up? What are the factors that are helping you grow and are helping you stay confident about achieving that goal? So, there are a bunch of different factors. Um, I think the US is still probably the the best market in the world that rewards innovation. Uh, and we are an innovation-driven company. And so, when new therapies come, you know, we we had a product for breast cancer in her two. Uh, we announced data for another breast cancer product. But as soon as new therapy comes, um, the US market is almost the first to provide access to patients for that new therapy. Uh, secondly, physicians are really, um, you know, we go to Congresses like ASCO where there's, you know, tens of thousands of oncology physicians. They're really into, um, looking at the data and making data-driven decisions. So, again, the, you know, the physicians want the best for their patients and patients are able to get access to medicines very quickly once, you know, drug is approved and so forth in the in the innovative space. In many other markets in the world, that whole process to get approval and then get access and reimbursement just takes a very long time. So that's one reason. Um, the second reason, uh, I think particularly beneficial for oncology medicines, uh, is the part D reform. Uh, so on one hand, the part D reform that was enacted hurts us because we are responsible for paying 20% in the catastrophic phase. But from a patient standpoint, if you're a patient, um, you know, in Medicare, your out of pocket is capped at $2,000. So you can get the best therapy and have no more to pay out of pocket, right? So being in that patient population and getting the best access to medicines and the best care and have your out of pocket limited, uh, is is also great for patients. Um, so I think it's it's where physicians and patients and innovation is rewarded. And that's why it's growing faster given our portfolio is all innovative medicines. So, so let's turn then to the manufacturing base rate and the investment that you're making in the US. And I have to ask about tariffs because we even as we discussed it this morning, this new EU sort of framework agreement, it's still sort of unclear. Are pharmaceuticals coming from the EU exempt? Are they not exempt? It seems a little unclear. So how under what assumption are you operating and how do you operate in that kind of environment? Um, yeah, so you know, I would say this is not a tariff is obviously new, but how we've been thinking about our strategic manufacturing, um, is probably goes back three, four years. So post COVID, we made a strategic decision because we're such a global company that we needed to have segregated supply chains. Um, so for example, uh, in in China and in the emerging markets, we supply a lot of that product from China. Um, in the US, majority of the product is supplied from the US and and so forth in Europe. There is, uh, you know, small minority of product, handful of products actually that we still import from Europe into the US. But we do have excess capacity in the US to manufacture those products. Uh, so what we're, you know, we have 11 manufacturing sites in in the US. So our intention once the tariffs, etc. were were announced and there was talks of tariffs, uh, in the short term was just manage through inventory, so build more inventory in in the US. Um, but we've also started tech transfers for those products which we do import and that those tech transfers would be completed, you know, within a within a year or so, so that we can be fully, you know, not just have the majority, but 100% of it being manufactured in in the US. Um, this new facility that we announced, uh, was part of the plan anyway, but that's a separate has nothing to do with tariffs. It's actually based on the demand that we see potentially for our cardiovascular for new cardiovascular medicine. So, um, but you know, you're right, I think there is a little bit of confusion on when the tariffs are going to be implemented. Um, there is from what I've heard, it is a 15%, but there's also talk that that's the cap. Uh, and, uh, the administration is sort of going to wait for the 232 investigation to actually put them into effect or decide. So, uh, in either case, I think we're very well prepared and and we probably have less exposure than than many companies. Related Videos Market's 'fuel' for further P/E expansion is 'nearing empty' Nvidia's TSMC order, Eli Lilly & Novo Nordisk sink, JPMorgan & Apple card Royal Caribbean, Merck, FuboTV: Trending Tickers Why Spotify stock is sinking double digits on Q2 earnings Sign in to access your portfolio

Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™
Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™

Yahoo

time13 hours ago

  • Yahoo

Postbiotics Market worth $224.8 million by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 29, 2025 /PRNewswire/ -- According to MarketsandMarkets™, The postbiotics market is estimated at USD 146.7 million in 2025 and is projected to reach USD 224.8 million by 2030, at a CAGR of 8.9%, from 2025 to 2030. The demand for postbiotics is projected to rise significantly, driven by growing consumer interest in microbiome health and the inherent limitations of probiotics and prebiotics in terms of viability and stability. Postbiotics, composed of non-living microbial cells and metabolites, offer proven health benefits without the need for live microorganisms. Their high stability under extreme processing conditions makes them ideal for a wide range of product formulations, including shelf-stable dietary supplements, functional foods, and beverages. Heat-treated bacterial strains, most notably Lactobacillus and Bifidobacterium, are widely recognized for their safety and scientifically supported benefits in gut, immune, and skin health. As consumer demand for microbiome-friendly solutions continues to grow, postbiotics are well-positioned to capture a larger share of the biotics market. Browse in-depth TOC on "postbiotics Market" 250– Tables30– Figures200– Pages Download PDF Brochure: Postbiotics in dry form to account for the fastest growth during the forecast period Postbiotic powders are versatile forms and attractive to consumers; they are expected to be the most rapidly growing during the forecast period because postbiotic powders offer a highly concentrated dose of bioactive compounds that can be easily incorporated into multiple food and drink formats such as smoothies, cereals, and snack bars-a boon for modern lifestyles with taste and convenience intact. From a manufacturing perspective, their dry, heat-stable nature makes it easy to process them without major modifications to existing equipment or product systems. In addition, the increasing disillusionment of consumers with conventional pills has made powders, gummies, and bars alternative delivery formats all the more popular. Although live probiotics may fail in such formats, postbiotics overcome this hurdle, much more so in dry form, making them the best solution for the manufacturers as well as health-conscious consumers. This combination of formulation ease, shelf stability, and growing end-user preference underlines why dry form postbiotics are expected to witness the steepest growth in future years. Cosmetics and personal care products segment to hold greater market share during the forecast period The trend of skinimalism increasingly embraces everything simple and multifunctional in skincare, thereby rapidly increasing the demand for postbiotics. Postbiotics address numerous benefits within a singular formulation. They have been introduced into cosmetics such as moisturizing creams intended to restore the hydrolipid barrier, anti-aging serums, and hair care containing agents that strengthen the scalp and improve hair condition. Coupling their multifunctionality with safety and stability makes postbiotics suitable for sensitive, acne-prone, or otherwise problematic skin. They do not pose the risk of microbial overgrowth as live probiotics do, making them ideal for products aimed at restoring the skin's natural microbiome balance. With increasing eco-awareness and health-consciousness among consumers, and as interest rises in Clean Beauty and microbiome-friendly skincare, especially into 2025, postbiotics are expected to establish themselves as the active ingredient of choice within modern beauty. The anti-inflammatory, antioxidant, and barrier-supporting qualities of postbiotics thus enhance their efficacy and safety and have driven the postbiotic to ever-rising prominence in next-generation cosmetics and personal care products. Request Sample Pages: European region to hold a significant market share in the global postbiotics market Most of the European consumers now claim to use dietary supplements, which reveals the growing trend toward preventive health and wellness. Growing consumer engagement creates a conducive environment for the postbiotic markets as people turn to scientifically validated, gut-friendly sources for postbiotics that can be easily incorporated into daily routines through supplements and functional foods. Active participation of the major regional players with respect to Associated British Foods plc (UK), can also be the reason of European postbiotic growth. In November 2023, AB Biotek Human Nutrition & Health (UK), subsidiary of ABF (UK) sealed a partnership deal with Tetra Pak (Switzerland) to come up with innovative postbiotic solutions for food & beverage, making it easy to incorporate postbiotics into mainstream products such as dairy, plant-based drinks, and snacks without any special equipment for their manufacturing. Such partnerships widen the simplicity of the formulation of products and visibility and accessibility of postbiotic-enriched offerings. With this innovation, seen by one of the dominant European players, ABF (UK), bringing postbiotics closer to consumers through the most consumed formats, public awareness is anticipated to grow quickly, and the market is expected to expand across the region. The report profiles key players such as Cargill, Incorporated (US), ADM (US), Kerry Group PLC (Ireland), dsm-firmenich (Netherlands), Associated British Foods plc (UK), BASF (Germany), Novozymes A/S, part of Novonesis Group (Denmark), International Flavors & Fragrances Inc (US), MCLS Europe B.V. (Netherlands), Phileo by Lesaffre (France), Lallemand Inc. (Canada), Sami-Sabinsa Group. (India), CJ CheilJedang Corp. (South Korea), Biotenova Sdn. Bhd. (Malaysia), and Bioprox Healthcare (France). Get 10% Free Customization on this Report: Browse Adjacent Reports @ Food and Beverage Market Research Reports & Consulting Related Reports: Functional Food Ingredients Market by Type (Probiotics, Protein & Amino Acids, Phytochemicals & Plant Extracts, Prebiotics, Omega-3 Fatty Acids, Carotenoids, Vitamins), Application, Source, Form, Health Benefits and Region - Global Forecast to 2029 Probiotics Market Size, Share, Analysis, & Growth Trends Report by Product Type (Functional Food & Beverages (FnB), Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel and Region - Global Forecast to 2029 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets Inc.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Insight: Our Website: Source: Logo: View original content: SOURCE MarketsandMarkets

Alcohol and Pancreatic Cancer: New Evidence About Risk
Alcohol and Pancreatic Cancer: New Evidence About Risk

Medscape

time13 hours ago

  • Medscape

Alcohol and Pancreatic Cancer: New Evidence About Risk

Does drinking alcohol increase the risk for pancreatic cancer? Researchers have long suspected it does, but the evidence has remained inconsistent. Now, a global study of more than two million people is firming up the case that a link exists. The study, which pooled data from 30 prospective cohorts, found that daily alcohol intake was associated with a 'modest' increased risk for pancreatic cancer in both women and men, regardless of smoking status. However, the extent of the risk depended somewhat on how the researchers modeled alcohol intake. One model, which mapped continuous increases in alcohol consumption, suggested there is no safe dose of alcohol — any amount can increase the risk for pancreatic cancer, though only by 3% for every additional 10 g of alcohol per day or about two thirds of a standard drink. The other model, which compared risk by alcohol volume categories, found that the risk does not become significant until a certain alcohol threshold — about two to three drinks per day for men and one to two for women. Still, overall, 'our findings provide new evidence that pancreatic cancer may be another cancer type associated with alcohol consumption, a connection that has been underestimated until now,' the study's senior author Pietro Ferrari, PhD, head of the Nutrition and Metabolism Branch at International Agency for Research on Cancer, said in a statement. The co-author Jeanine Genkinger, PhD, MHS, had a stronger take on the findings. 'I think this shows that alcohol use is a robust risk factor for pancreatic cancer,' said Genkinger, associate professor, epidemiology, Columbia University Mailman School of Public Health, New York City, noting that even more moderate drinking levels— no more than one drink for women and two for men — might be enough to boost pancreatic cancer risk. How Much of a Risk? The latest data, published in PLoS Medicine, come at a time of increased attention to the alcohol-cancer link. Earlier this year, then-US Surgeon General Vivek Murthy, MD, issued an advisory calling for cancer warnings to be added to alcohol labels. Major cancer organizations have determined alcohol to be an established risk factor for seven cancer types : those of the oral cavity, larynx, pharynx, esophagus, liver, breast, and colon/rectum. Despite the strong suspicion that drinking alcohol also contributes to pancreatic cancer risk, this aggressive cancer has not yet made the official list. The major reason is that the evidence surrounding an alcohol-pancreatic cancer link has been deemed 'inconsistent,' 'suggestive,' and 'inconclusive' by expert panels. Studies have been hampered by difficulties separating alcohol use from smoking — a known risk factor for pancreatic cancer — as well as varying findings by alcohol type and geographic location. In addition, certain studies highlighting a link have indicated that any association between alcohol and pancreatic cancer is driven only by more extreme drinking habits — more than four drinks a day, and sometimes as high as nine drinks. The latest analysis, Genkinger said, helps clarify uncertainty surrounding the alcohol-pancreatic cancer link, which is especially important for 'a disease where we don't have that many modifiable risk factors.' The findings are based on cohorts spanning four continents, all part of the Pooling Project of Prospective Studies of Diet and Cancer. Just under 2.5 million cancer-free participants were recruited between 1980 and 2013 (median age, 57 years), of whom 70% were alcohol drinkers, 47% were never-smokers, and 64% were alcohol drinkers and never smokers. Most study participants were from North America (60%), followed by Europe or Australia (32%) and Asia (8%). Alcohol intake was modeled in two ways: continuously for every 10 g/d increase and by volume threshold, using 0.1 to < 5 g/d as the reference for nondrinkers. For context, in the US, the amount of alcohol in a standard drink is defined as 14 g of pure alcohol — equivalent to a 12-ounce can of regular beer, a 5-ounce glass of wine, or a 1.5-ounce shot glass of distilled spirits. Over a median of 16 years, the researchers observed 10,067 incidents of pancreatic cancers. In the continuous model, the risk for pancreatic cancer rose by 3% for every additional 10 g of alcohol consumed per day (hazard ratio [HR],1.03; 95% CI, 1.02-1.04). This association remained consistent and significant among women and men (HR, 1.03 for both), current smokers (HR, 1.03), former smokers (HR, 1.02), and never-smokers (HR, 1.03), and across cohorts from Australia, Europe, and North America (HR, 1.03 for all), though not Asia (HR, 1.00). The research team also found evidence that the type of alcohol mattered: Alcohol from beer and liquor/spirits was associated with a significantly increased risk for pancreatic cancer (HR, 1.02 and 1.04, respectively) but alcohol from wine was not (HR, 1.00). This finding is in line with some previous studies suggesting that wine may have a different relationship with cancer risk compared with other alcoholic beverages. But Genkinger pointed out, this finding could 'reflect the ways in which people tend to drink different types of alcohol.' Wine, she noted, is often part of a meal, and people who favor wine may be less likely to binge drink than those who typically choose other types of alcohol. This study, however, did not survey participants about specific drinking patterns, including binge-drinking. In the threshold model, however, the increased risk only became significant once alcohol intake reached a certain level. For women, drinking one to two standard drinks per day raised their risk for pancreatic cancer by 12% compared with little to no drinking. For men, the threshold was a little higher: Consuming two to four drinks a day was associated with a 15% increase in risk, whereas drinking more than that was tied to a 36% greater risk. Overall, this research contributes to the growing body of evidence that pancreatic cancer should be added to the official alcohol-cancer risk list, according to Alison Klein, PhD, MHS, professor of oncology, pathology, and epidemiology, at Johns Hopkins School of Medicine, Baltimore, who was not involved in the research. Having the Conversation The recent Surgeon General's advisory encouraged clinicians to inform their patients that drinking is a cancer risk factor — something unknown to most Americans, according to recent survey findings. 'I think this study is a good reminder to all of us to talk to our patients about their alcohol use,' said Edward Thomas Lewis III, MD, an addiction psychiatrist and clinical assistant professor at the Medical University of South Carolina, Charleston, South Carolina. Providers can take opportunities for those discussions during routine care, such as when prescribing a medication that can interact with alcohol or when a patient's health condition, such as high blood pressure or heart disease, can be exacerbated by drinking. 'I think these are opportunities to really remind people about moderation,' Lewis said, 'and to talk about some of the individual risk factors that may cause someone to make changes related to their drinking.' It's also possible that drinking might interact with certain genetic variants to modify pancreatic cancer risk — an avenue Klein and colleagues are exploring. What's challenging, Lewis said, is advising patients on what level of drinking is 'Okay,' given that even lower levels of alcohol consumption — around one to two drinks per day — may carry some risk. 'There is no zero-risk alcohol use,' Lewis said. But, he added, people do not necessarily have to abstain to see benefits, either. 'So it may be that a patient, at the end of the day, is able to reduce their alcohol consumption by two or three standard drinks over a given week. That still has a positive net effect,' he said. Another challenge is patients often don't know what a 'standard drink' looks like and can underestimate how much they drink. Showing patients visual examples — such as these— can be an eye-opener, Lewis said. Given the associations between drinking alcohol and many health outcomes, Genkinger said, it's important for clinicians to discuss alcohol use, just as they would discuss physical activity and healthy body weight. 'These are all lifestyle factors that have an impact on numerous disease outcomes, not only pancreatic cancer,' she said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store